Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E–mutant metastatic colorectal cancer: Safety lead-in results from the phase III BEACON Colorectal Cancer Study

Eric Van Cutsem, Sanne Huijberts, Axel Grothey, Rona Yaeger, Pieter Jan Cuyle, Elena Elez, Marwan Fakih, Clara Montagut, Marc Peeters, Takayuki Yoshino, Harpreet Wasan, Jayesh Desai, Fortunato Ciardiello, Ashwin Gollerkeri, Janna Christy-Bittel, Kati Maharry, Victor Sandor, Jan H.M. Schellens, Scott Kopetz, Josep Tabernero

Research output: Contribution to journalArticleResearch

61 Citations (Scopus)

Abstract

Copyright © 2019 American Society of Clinical Oncology. All rights reserved. PURPOSE To determine the safety and preliminary efficacy of selective combination targeted therapy for BRAF V600E–mutant metastatic colorectal cancer (mCRC) in the safety lead-in phase of the open-label, randomized, three-arm, phase III BEACON Colorectal Cancer trial (ClinicalTrials.gov identifier: NCT02928224; European Union Clinical Trials Register identifier: EudraCT2015-005805-35). PATIENTS AND METHODS Before initiation of the randomized portion of the BEACON Colorectal Cancer trial, 30 patients with BRAF V600E–mutant mCRC who had experienced treatment failure with one or two prior regimens were to be recruited to a safety lead-in of encorafenib 300 mg daily, binimetinib 45 mg twice daily, plus standard weekly cetuximab. The primary end point was safety, including the incidence of dose-limiting toxicities. Efficacy end points included overall response rate, progression-free survival, and overall survival. RESULTS Among the 30 treated patients, dose-limiting toxicities occurred in five patients and included serous retinopathy (n = 2), reversible decreased left ventricular ejection fraction (n = 1), and cetuximab-related infusion reactions (n = 2). The most common grade 3 or 4 adverse events were fatigue (13%), anemia (10%), increased creatine phosphokinase (10%), increased AST (10%), and urinary tract infections (10%). In 29 patients with BRAF V600E–mutant tumors (one patient had a non–BRAF V600E–mutant tumor and was not included in the efficacy analysis), the confirmed overall response rate was 48% (95% CI, 29.4% to 67.5%), median progression-free survival was 8.0 months (95% CI, 5.6 to 9.3 months), and median overall survival was 15.3 months (95% CI, 9.6 months to not reached), with median duration of follow-up of 18.2 months (range, 16.6 to 19.8 months). CONCLUSION In the safety lead-in, the safety and tolerability of the encorafenib, binimetinib, and cetuximab regimen is manageable and acceptable for initiation of the randomized portion of the study. The observed efficacy is promising compared with available therapies and, if confirmed in the randomized portion of the trial, could establish this regimen as a new standard of care for previously treated BRAF V600E–mutant mCRC.
Original languageEnglish
Pages (from-to)1460-1469
JournalJournal of Clinical Oncology
Volume37
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint Dive into the research topics of 'Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E–mutant metastatic colorectal cancer: Safety lead-in results from the phase III BEACON Colorectal Cancer Study'. Together they form a unique fingerprint.

  • Cite this

    Van Cutsem, E., Huijberts, S., Grothey, A., Yaeger, R., Cuyle, P. J., Elez, E., Fakih, M., Montagut, C., Peeters, M., Yoshino, T., Wasan, H., Desai, J., Ciardiello, F., Gollerkeri, A., Christy-Bittel, J., Maharry, K., Sandor, V., Schellens, J. H. M., Kopetz, S., & Tabernero, J. (2019). Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E–mutant metastatic colorectal cancer: Safety lead-in results from the phase III BEACON Colorectal Cancer Study. Journal of Clinical Oncology, 37, 1460-1469. https://doi.org/10.1200/JCO.18.02459